What is Oseltamivir API? Uses in Influenza Treatment

Oseltamivir phosphate is the active ingredient in oral flu antivirals. It is a prodrug: the liver converts it to oseltamivir carboxylate, which blocks the viral neuraminidase enzyme so new virus particles stay stuck to infected cells. It treats influenza A and B, works best when started within 48 hours of symptoms, and also prevents infection after exposure. Bio-Synth manufactures Oseltamivir Phosphate API in Hyderabad in USP grade, with IP, EP and BP grades available.

Oseltamivir Phosphate API at a Glance

Oseltamivir Phosphate API is the phosphate salt of oseltamivir, an antiviral in the neuraminidase inhibitor class. It goes into the oral capsules and suspensions prescribed during flu season, and it has been in clinical use since its first US approval in 1999.

Like other active pharmaceutical ingredients, it is the part of the medicine that does the therapeutic work. The capsule shell, fillers and suspension base only deliver it.

Finished-product strengths are stated as oseltamivir base, not as the salt. The US label lists 30, 45 and 75 mg capsules and a powder constituted to a 6 mg/mL oral suspension. Oseltamivir base is CAS 196618-13-0, C16H28N2O4, 312.41 g/mol, so one kilogram of the phosphate salt carries roughly 761 g of base. Every formulation and costing sheet has to get that conversion right.

How Oseltamivir Works Against Influenza

Oseltamivir is an ethyl ester prodrug. After an oral dose, esterases, mainly in the liver, convert it to oseltamivir carboxylate, the active form. According to the US prescribing information, at least 75% of an oral dose reaches the circulation as the carboxylate.

The carboxylate targets neuraminidase, an enzyme on the surface of the influenza virus. When new virus particles bud from an infected cell, neuraminidase cuts them loose. Block it and they stay tethered to the cell, so the infection spreads more slowly through the airway. It acts on the neuraminidase of both influenza A and influenza B.

Two points follow for anyone handling the API. The drug limits the release of new virus rather than clearing virus already made, so the benefit is greatest when treatment starts early. And the molecule has three stereocentres, of which only the (3R,4R,5S) configuration is active. Isomer control is a core quality attribute, not a detail.

Uses of Oseltamivir in Influenza Treatment

Medicines made from oseltamivir phosphate have two labelled uses: treating influenza and preventing it. The US prescribing information sets out who each use covers.

Treating hospitalised and higher-risk patients

CDC guidance is more specific than the label for sicker patients. It recommends antiviral treatment as soon as possible for anyone with suspected or confirmed influenza who is hospitalised, has severe, complicated or progressive illness, or is at higher risk of complications. The decision should not wait for laboratory confirmation. For hospitalised patients, CDC names oral or enterically administered oseltamivir as the recommended antiviral.

WHO keeps oseltamivir on the complementary list of its Model List of Essential Medicines, restricted to severe illness from confirmed or suspected influenza in critically ill hospitalised patients. In 2025 the 6 mg/mL powder for oral liquid was added to the children’s list.

Preventing influenza after exposure

In care homes and other institutions with an outbreak, CDC recommends chemoprophylaxis for exposed residents, using oral oseltamivir or inhaled zanamivir for at least two weeks. The label is clear that none of this replaces the annual flu vaccine.

Safety, Resistance and Limits of Use

Nausea, vomiting and headache are the most common adverse reactions in the label’s treatment studies. The label also warns that people with influenza, including those taking oseltamivir, may be at higher risk of confusion or abnormal behaviour early in the illness, and should be watched for it.

Oseltamivir works only against influenza viruses. It does not treat bacterial infections and has not been shown to prevent the bacterial complications that can follow flu. The reverse also holds: antibiotics have no effect on the influenza virus itself.

Resistance is low for now. CDC reports that reduced susceptibility to neuraminidase inhibitors among circulating viruses is currently very low, but that this can change, and that resistance can emerge during treatment, particularly in young children and immunocompromised patients. An H275Y mutation in the neuraminidase of A(H1N1)pdm09 viruses confers oseltamivir resistance, and CDC describes its spread between people as uncommon at present. The label asks prescribers to consider local susceptibility patterns.

What Formulators Check in Oseltamivir Phosphate API

Oseltamivir phosphate has monographs in the USP and the Ph. Eur./BP. Beyond assay and related substances, a pharmacopoeial monograph calls for description, identification by infrared absorption and HPLC retention, water content, residue on ignition, elemental impurities under ICH Q3D, and residual solvents within ICH Q3C class limits. With three stereocentres, the enantiomeric and diastereomeric results deserve the first read on any certificate of analysis.

Some finished-product makers add their own requirements on top of the monograph. A WHO public assessment report for one prequalified generic, for example, lists particle size distribution and polymorphic form as additional user requirements.

Meeting those limits batch after batch depends on how each step of the API manufacturing process is controlled. The final salt formation with phosphoric acid is a crystallisation step, and its stoichiometry, solvent system and cooling profile set the water content, crystal habit and flow the formulator inherits.

Regulated markets expect the API to be made under ICH Q7, the international GMP guideline for active pharmaceutical ingredients. Destination-specific API regulations and standards then decide which documents have to travel with each shipment.

Oseltamivir Phosphate API from Bio-Synth

Bio-Synth manufactures Oseltamivir Phosphate API at its Balanagar site in Hyderabad and has made bulk drugs since 1943. The API is offered in USP grade, with IP, EP and BP grades also available. A batch certificate of analysis is issued for each production lot, a safety data sheet travels with commercial orders, and a certificate of pharmaceutical product can be applied for where the importing authority requires one.

Manufacturing follows ICH Q7 principles, and every batch is released through the site’s quality control and assurance system. The site holds ISO 9001:2015 certification from DNV (certificate 156792-2014-AQ-IND-UKAS) for the “development, manufacture and sale of active pharmaceutical ingredients (APIs), drug intermediates, biological products & liver injectable”.

Demand follows the flu season, and buyers generally contract ahead of the northern hemisphere winter. Lead times, supplier checks and seasonal timing are covered in the oseltamivir phosphate API sourcing guide.

To request a quotation or a qualification sample, contact Bio-Synth with the grade, quantity and destination market you need.

FAQs

What is oseltamivir phosphate API used for?

It is the active ingredient in oral medicines that treat influenza A and B and prevent infection after exposure. Treatment is labelled for patients 2 weeks and older who have had symptoms for no more than 48 hours, and prophylaxis for patients 1 year and older.

How does oseltamivir work?

It is a prodrug that the liver converts to oseltamivir carboxylate. The carboxylate blocks influenza neuraminidase, the enzyme that releases new virus particles from infected cells, which slows the spread of infection.

Is oseltamivir an antibiotic?

No. Oseltamivir is an antiviral that acts only on influenza viruses. It does not treat bacterial infections and has not been shown to prevent the bacterial complications of flu.

How soon should oseltamivir treatment start?

As soon as possible. The US label covers patients who have had symptoms for no more than 48 hours, and CDC advises that treatment of hospitalized and higher-risk patients should not wait for laboratory confirmation.

What is the CAS number of oseltamivir phosphate?

204255-11-8 for the phosphate salt used as the API. Oseltamivir free base is a different substance with CAS 196618-13-0.

Which grades of Oseltamivir Phosphate API does Bio-Synth supply?

Bio-Synth supplies Oseltamivir Phosphate API in USP grade, with IP, EP and BP grades also available. A batch certificate of analysis is issued for each production lot.